author-photo

Masahiro Kitada

Asahikawa Medical University

77

Papers

372

Citations

Citation Trend

Filter By

Papers (51) Sort By

Journal Conference Others

The feasibility of circulating tumor DNA analysis as a marker of recurrence in triple-negative breast cancer

2021 Oncology Letters
Show All
- Source
- Cite
- Save
Citations (1)
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).

2021 International Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study).

2020 Investigational New Drugs
Show All
- Source
- Cite
- Save
Citations (4)
Erratum: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) (Trials (2020) 21 (391) DOI: 10.1186/s13063-020-04341-y)

2020 Trials
Show All
- Source
- Cite
- Save
Citations (0)
Photodynamic Diagnosis for Pleural Disseminated Lesions of Lung Cancer Using a Combination of 5-Aminolevulinic Acid and Autofluorescence Observation System.

2020 Annals of Thoracic and Cardiovascular Surgery
Show All
- Source
- Cite
- Save
Citations (0)
The value and practical utility of intraoperative touch imprint cytology of sentinel lymph node(s) in patients with breast cancer: A retrospective cytology-histology correlation study

2020 CytoJournal
Show All
- Source
- Cite
- Save
Citations (0)
Novel ALK -specific mRNA in situ hybridization assay for non-small-cell lung carcinoma

2020 Translational lung cancer research
Show All
- Source
- Cite
- Save
Citations (5)
Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).

2020 Trials
Show All
- Source
- Cite
- Save
Citations (10)
Randomized, optimal dose-finding, phase II study of tri-weekly nab-paclitaxel in patients with metastatic breast cancer (ABROAD).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)